Limited Improvement of Tumour Diagnosis by the Simultaneous Determination of Carcinoembryonic Antigen (CEA) and of a Tumour-Associated CEA-Related Antigen of Mr 128000 in Serum by Wagener, C. et al.
Wagener et al.: Determination of CEA and of a CEA-related antigen of Mr 128000 in serum 643
J. Clin. Chem. Clin. Biochem.
Vol. 27, 1989, pp. 643-652
© 1989 Walter de Gruyter & Co.
Berlin · New York
Limited Improvement of Tumour Diagnosis by the Simultaneous
Determination of Carcinoembryonic Antigen (CEA) and of a
Tumour-Associated CEA-Related Antigen of Mr 128000 in Serum
By C. Wagener
Abteilung für Klinische Chemie der Medizinischen Klinik, Universitätskrankenhaus Eppendorf, Hamburg, Bun-
desrepublik Deutschland
Lucia Wickert
Institut för Klinische Chemie und Pathobiochemie der Medizinischen Fakultät der RWTH, Aachen, Bundesre-
publik Deutschland and
W, Meyers
Institut für Medizinische Statistik und Dokumentation der Medizinischen Fakultät der RWTH, Aachen, Bun-
desrepublik Deutschland
(Received April 6/July 18, 1989)
Summary: Two biotin-avidin based enzyme immunoassays were developed using three monoclonal anti-CEA
antibodies with distinct epitope- and antigen-specificities. A broadly cross-reactive monoclonal anti-CEA
antibody (T84.1) was immobilized on a solid support. Either monoclonal antibody T84.66 or CEA. 11 was
used äs the second, biotin-labeled monoclonal antibody. Both antibodies do not cross-react with normal
granulocytes or bile canaliculi. Monoclonal antibody CEA. 11 binds to CEA and to an antigen with a relative
rnolecular mass of 128000 present in extracts from solid carcinomas. Monoclonal antibody T84.66 does not
cross-react with the antigen of 128000. After adsorption of tumour extracts to a CEA-specific immuno-
sorbent, residual activity was measurable by the CEA. 11 assay, but not by the T84.66 assay. Serum samples
(n = 726) from patients with malignant and non-malignant disease, äs well äs from healthy volunteers, were
analysed by both immunoassays and by two commercial CEA immunoassays. In comparison with the T84.66
assay and the cpmmercial assays, the CEA. 11 assay did not significantly increase the sensitivity or specificity
of tumour diagnosis.
Introduction ^ genes: ̂  ?ene encoding CEA (2j 3), the non-specific
The carcinoembryonic antigen (CEA) is a marker of cross-reacting antigen (NCA) (4, 5), and the biliary
human colorectal carcinomas, CEA is a well defined glycoprotein I (6, 7). According to a recent study, the
glycoprotein with a relative molecular mass (Mr) of primary transcript of the biliary glycoprotein I gene
180000 (for review see I.e. (1)). Antibodies induced is modified by alternative splicing (7). This finding
against CEA may cross-react with a variety of anti- suggests the existence of several biliary glycoprotein
gens present in normal and cancerous tissues, body I-related antigens. Our own data indicate that normal
fluids, effusions, and faeces. As shown recently, these plasma contains two different biliary glycoprotein I-
antigens are the products of at least three distinct related antigens (8, 9).
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In previous studies, we described five monoclonal
antibodies against CEA which bind to different epi-
topes of the antigen (10—12). Two of these antibodies
preferentially bind to tumour tissues (10, 13). The
antigen specificities of both antibodies are distinct.
One monoclonal antibody (CEA. 11), in addition to
CEA, binds a tumour-associated antigen with a rel-
ative molecular mass of 128000. The second mono-
clonal antibody (T84.66) does not cross-react with the
latter antigen (14). This antigen may be similar to or
identical with CEAiow described by Hammerström and
co-workers (15). Since it is not yet established whether
the CEA-related antigen of MT 128000 is a product
of an äs yet undescribed member of the CEA gene
family, whether it is a product of alternatively spliced
mRNA, or whether it is generated by posttransla-
tional modifications, the antigen will be designated
"CEA-related antigen of MT 128000 (CRA-128)".
Despite of the fact that the nature of CRA-128 is not
firmly established, the antigen specificity of mono-
clonal antibody CEA. 11 has been confirmed by other
investigators (16, 17). Suzuki et al. (16) described an
immunoassay which measured an antigen similar to
CRA-128 in addition to CEA. In some serum speci-
mens from tumour patients, significantly elevated an-
tigen concentrations remained after adsorption to a
CEA-specific immunadsorbent. However, no Infor-
mation on the relative frequency of such specimens
among sera from tumour patients was given.
Since CRA-128 occurs in a high percentage of tumour
tissues (unpublished observation), we addressed the
questions of whether the serum determination of CEA
+ CRA-128 can increase the diagnostic sensitivity of
tumour diagnosis and whether CRA-128 may be as-
sociated with tumours at certain sites.
Materials and Methods
Monoclonal antibodies and CEA Standard
The monoclonal anti-CEA antibodies were induced, character-
ized and purified äs described (10, 11). The monoclonal anti-
hepatitis B surface (Hbs) antigen antibody was kindly donated
by Hoffmann-La Röche, Basel, Switzerland. All monoclonal
antibodies used in this study were of subclass Igd. The CEA
Standard preparation, which was purified according to Prii-
chard & Todd (18), was supplied by Dr. Shively, Beckman
Research Institute of the City of Hope, Duarte, CA, U. S. A.
Biotinylation procedure
Monoclonal antibodies were biotin-labelled äs described (19,
20). As antibodies, the monoclonal antibodies T84.66 and
CEA. 11 were used. Molar ratios of N-hydrosuccinimidobiotin
(Mr = 341.4) to IgG (Mr = 150000) in the ränge of 10-600
were tested, in order to find which ratio yields the highest
sensitivity in the solid phase EIA. Using monoclonal antibody
T84.66, a ratio of 60—70 was found to be optimal. This ratio
was also adopted for monoclonal antibody CEA. 11.
Preparation of F(ab)2-fragments
The IgGj fraction of monoclonal antibody T84.1 was purified
from ascitic fluid over protein^A sepharose (21). IgGj (6—12
g/l) was digested with pepsin äs described (22). The cleavage
products were characterized by gel permeation HPLC (TSK
3000, LKB, Gräfelfing, F. R. Genhany) and SDS-PAGE under
reducing and nön-reducing conditions.
CEA-immunoassays
Polystyrene beads were coated with the Igd fraction or F(ab)2-
fragments of monoclonal antibody T84.1. Per 100 beads, 30 ml
of a 20 mmol/1 sodium acetate buffer, pH 5.5, containing 10
mg/1 of antibody IgG ör antibody fragiments, respectively, was
used. Coating was performed overnight at room temperature.
Blocking pf unspecific binding sites and storage of the beads
was performed in phosphate buffered saline containing 20 mg/1
bovine serum albumin, The CEA Standard was dissolved in
phosphate buffered saline containing 10 mg/1 bovine serum
albumin. Either monoclonal antibody T84.66 or CEA. 11 was
used äs the second biotin-labelled antibody, The antibodies
were dissolved in 0.1 mol/1 potassium phosphate buffer, pH 7.3,
containing foetal calf serum (200 ml/l), 9.2 ml/l Tween 20 and
30 ml/l normal mouse serum. The final concentratiön of biotin-
labelled monoclonal antibody T84.66 was 2.7 mg/1. A final
concentration of 5.7 mg/1 was used for F(ab)2-fragments from
monoclonal antibody CEA. 11.
Sample tubes contained the following Solutions (voluöies in
brackets): serum (100 ); phosphate buffered saline/bovine
serum albumin (50 ); Solutions of biotinylated monoclonal
antibodies (50 ). Standard tiibes were prepared äs foliows:
normal seriim from a serum pool with a CEA^-concentration of
< l g/l (100 ); CEA-standard in phosphate buffered saline/
bovine serum albumin (50 ); Solutions of biotinylated mono-
clonal antibodies (50 ). Subsequently, immobilized mono-
clonal antibody T84.1 was added. For the T84.66 EIA, undig-
ested IgGt was used. The incübation time was l h (37 °C). For
the CEA. 11 EIA, immobilized F(ab)2-fragments from mono^
clorial antibody T84.1 were incubated for 17 h at room tem-
perature. After the appropriate incübation time, the beads were
washed 3 times with 0.1 mol/1 potassium phosphate buffer, pH
7.3. Subsequently, 200 of avidin-peroxidase conjugate
(Sigma, Taufkirchen, F. R. Germany) diluted in 0.2 mol/1 po-
tassium phosphate buffer, pH 6.5, containing 200 ml/1 biotin^
free foetal calf serum, was added. The concentration of avidin-
peroxidase conjugate was chosen äs the highest concentration
yielding negligible unspecific binding. After 30 min at room
temperature, the beads were washed 3 times in 0.1 mol/1 citrate
buffer, pH 5.0, and 300 of Substrate solution containing
6 mmol hydrogen peroxide and 40 mmol o-phenylenediamine
(Sigma) per litre of 0.1 mol/1 citrate buffer, pH 5.0, were added.
After incübation for 30 min at room temperature in the dark,
the reaction was stopped with 2 ml of a l mol/1 HCl-solution.
The absorbance was detennined at 492 nm.
Immunoassays for anti-mouse IgG binding activity
In these assays, antibody T84.1 was replaced by a monoclonal
anti-HBs antibody om the solid phase. Antibody CEA. 11 or
T84.66 was used äs the secoad antibody. With the exception of
these modifications, the single incübation Step assays were per-
formed äs in the original CEA assays.
Extraction of tissues and Western biot
The extraction of tumour tissues, immunosorbent purification,
and Western blots were performed äs described (14).
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Commercial CEA-immunoassays
Commercial CEA-immunoassays were obtained from HofT-
niann-La Röche, Basel, Switzerland, and from Abbott, Wies-
baden, F. R. Germany. The assays were performed according
to the instructions of the manufacturers.
Serum specimens
CEA determinations were performed in 726 serum samples
using four different immunoassays (2 assays developed in our
laboratory, 2 coramercial assays). Serum samples were obtained
from the following groups of persons or patients (number of
samples in brackets):
Healthy blood donors, non-smokers (98);











other non-malignant diseases of the gastrointestinal tract (52);
liver cirrhosis (46);
other non-malignant liver diseases (14);
pancreatitis (13);
non-malignant diseases of the gail bladder (9);
non-malignant lung disease (51);
non-malignant renal disease (60);
other non-malignant conditions (32).
Statistical procedures
The following non-parametric tests were used: Spearman's coef-
ficient of rank correlation, Kolmogorov-Smirnov test, and Wil-
coxorfs matched pairs signed rank test.
Results
Establishment of immunoassays, elimination
of anti-mouse IgG activity in sera
Two additive solid-phase enzyme immunoassays were
established using three monoclonal anti-CEA anti-
bodies with different epitope- and antigen-speeifici-
ties. For both immunoassays, the broadly cross-re-
active, high affinity antibody T84.1 was adsorbed to
a solid support. Either monoclonal antibody T84.66
or monoclonal antibody CEA. 11 was used äs the
second antibody. For simplicity, the immunoassay
with monoclonal antibody T84.66 äs seeond antibody
will be designated "T84.66 assäy", and the immu-
noassay with monoclonal antibody CEA. 11 äs second
antibody will be designated "CEA. 11 assay". In ad-
dition to the above immunoassays, an immunoassay
for the detection of anti-mouse IgG binding activity
in sera was developed. Instead of monoclonal anti-
body T84.1, a monoclonal anti-HBs antibody was
immobilized on a solid support. Either monoclonal
antibody CEA. 11 or T84.66 was used äs the second
antibody. This immunoassay, in which no CEA-re-
lated antigens are measured, will be designated "in-
terference assay". All immunoassays were based on
the biotin-avidin System. Avidin-peroxidase conjugate
was added to the biotin-labelled second antibody
bound to the antigen. The colour reaction was devel-
oped with H2O2/o-phenylenediamine äs Substrate.
Initially, both the T84.66 and CEA. 11 immunoassay
versions, were established with native IgGi of mono-
clonal antibody T84.1 adsorbed to the solid support.
In both initial versions, normal mouse serum was not
added. When normal sera were investigated by the
initial Version of the CEA. 11 immunoassay, CEA-
values exceeding 10 g/l were occasionally observed.
This effect was absent in the T84.66 immunoassay. A
preliminary comparison of the CEA-concentrations
determined by the T84.66 and CEA. 11 immunoassays
with the values obtained from a commercial assay
(Abbott) revealed significant differences in a serum
sample from a patient who had received therapeutic
doses of a murine monoclonal antibody.
In order to eliminate the unspecific interferences,
serum specimens from the above patient and from an
apparentiy healthy person were further analysed.
After addition of 10 ml/l mouse serum (final concen-
tration) to the T84.66 and CEA. 11 immunoassay,
respectively, the CEA-concentrations in the patient's
sample decreased to concentrations comparable with
those measured in a commercial assay (tab. 1). The
addition of normal mouse serum did not affect the
elevated CEA level measured in the normal serum
sample by the CEA. 11 immunoassay (tab. 1). The
interfering serum samples were further analysed by
an interference assay in which the anti-CEA mono-
clonal antibody adsorbed to the solid phase was re-
placed by a monoclonal antibody of identical subclass
(IgGj) with a specificity unrelated to CEA. As shown
in figure l, the normal serum interfered only after a
prolonged incubation time, irrespective of which anti-
CEA monoclonal antibody was used äs second anti-
body. In contrast, the response with tumour serum
apprpached a maximum after an incubation time of
only l h. The interfering effect of the normal serum
in the CEA. 11 immunoassay could not be suppressed
by the addition of non-immune mouse IgG at con-
centrations of up to l mg/reaction volume (not
shown). In order to eliminate the unspecific interfer-
ence of the normal serum in the CEA. 11 immunoas-
say, F(ab)2-fragments from monoclonal antibody
T84.1 were prepared. As shown in table l, the meas-
ured CEA value decreased to 1.0 g/l when F(ab)2
instead of native IgG fragments were adsorbed to the
solid support. With the revised Version of the CEA. 11
J. Clin. Chem. Clin. Biochem, / Vol. 27,1989 / No. 9
646 Wagener et al.: Determination of CEA and of a CEA-related antigen of MT128000 in serum






















Tab. 2. Assay characteristics of two double monoclonal, biotin-






























































a) concentration corresponding to the zero Standard -h 3 SD
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Fig. 1 Effect of incubation time on the absorbance in the
CEA. 1 1 and T84.66 interference assays (anti-HBs an-
tibody on the solid phase) using a normal Serum sample
(P) and a serum sample from a patient treated with




immunoassay, CEA concentrations exceeding 10
were not observed in sera from healthy blood donors
or in sera from healthy smokers.
Characterization of immunoassays
The characteristics of the final assay versions of the
immunoassays (sensitivity, measuring r nge, recovery,
precisiori) are shown in tabie 2. In dilution experi-
ments, the dose-response curves of tunaour extracts
ran parallel with the Standard cufVes (tab. 3).
Specificities of immunoassays
The specificities of the two immunoassays were char-
acterized by the use of tumour extracts in which high
amounts of the tumour-asspciated CEA variant of
Mτ 128000 could be demonstrated by Western blotS;
Figure 2 sh ws a Western blot of an extract fr rn a
primary rectal carcinoma el ted from a T84.1 im-
m nosorbent. Monoclonal antibody T84.66 (lane 1)
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Fig. 3. Schematic presentation of the antigen specificities of the
T84.1/T84.66- and T84.1/CEA. 11-immunoassays.
> biotin; avidin
Fig. 2. Western blots of CEA and CRA-128 isolated from a
primary rectal carcinoma. The rectal carcinoma extract
was purifled over a monoclonal antibody with broad
cross-reactivity (T84.1) prior to Western blot analysis.
Lane 1: monoclonal antibody T84.ll; lane 2: mono-
clonal antibody CEA. 11
For methodological details see I.e. (12).
exclusively binds to an antigen with a Mr of only
177 000. According to MT and immunoreactivity, e. g.,
binding of each fo the five monoclonal anti-CEA
antibodies with different epitope specificities, this an-
tigen is probably identical with CEA. In addition to
CEA, monoclonal antibody CEA. l1 binds an addi-
tional antigen with a Mr of 128 000 (lane 2). Antigen
concentrations were detennined in extracts from the
rectal and from a gastric carcinoma prior to and after
adsorption to a T84.66 immunosorbent. In both tüm-
our extracts, the CEA concentrations determined by
the CEA. 11 immunoassay were higher than those
measured by the T84.66 immunoassay (tab. 4). After
adsorption to a T84.66 immunosorbent, no CEA
could be measured by the T84.66 immunoassay. In
the CEA. 11 immunoassay, a significant CEA-activity
remaiiied after immurioadsorption. Figure 3 gives a
schematic presentation of the specificities of both
immunoassays.
Tab. 4. CEA-concentratipns in tissue extracts before and after













* 29.0 < 0.001
108.5 <0.001
Determination of CEA in serum samples
CEA was detennined in a total of 726 serum samples
from healthy persons and from patients with non-
malignant and malignant disease, using four different
immunoassays. Table 5 shows the distribution of
measured CEA-concentrations in sera from healthy
blood donors. In the commercial assays, the absorb-
ance values of significant fractions of samples were
below the absorbance values of the zero Standards.
This finding affects the values obtained for the 95%-
percentiles.
Tab. 5. Percentiles of CEA-concentrations [\igß] in healthy





































The correlation of CEA-concentrations in serum sam-
ples from patients with malignant disease is demon-
strated in figure 4 and table 6. The T84.66 immu-
noassay shows a good correlation with two commer-
cial assays. The CEA. 11 immunoassay shows a lower
correlation to the T84.66 assay and to the commercial
assays.
Figure 5 demonstrates the distributions of CEA con-
centrations in different malignant and non-malignant
diseases. In colorectal cancer, the median of the CEA
concentrations measured by the CEA. 11 assay is
higher than the corresponding median of the T84.66
assay. This difference, however, is not statistically
significant. In mammary cancer, the CEA-concentra-
tions obtained by the T84.66 assay were significantly
higher than the corresponding concentrations deter-
mined by the CEA. 11 assay. It is interesting to note
that in the group of patients with non-malignant
kidney disease, including a high percentage of patients
with chronic renal failure, the CEA. 11 assay meas-
ured significantly higher concentrations than the
T84.66 immunoassay.
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Fig. 4a—d. Correlation of measured CEA-concentrations in serum specimens from 293 patients with malignant disease s
determined by different CEA immunoassays. In the case of CEA-concentrations above the upper limit of the
measuring r nge, the concentration in the diluted samples are shown.
Tab. 6. Speannan's coefficient of rank correlation of different
















The discrimination by the T84.66 and CEA. 11 im-
munoassays between sera from normal persons and
patients with non-malignant disease on the one hand
and with malignant disease on the other hand were
analysed by the Kolmogorov-Smirnov-test (flg. 6).
When sera from patients with colorectal cancer are
compared with sera from patients with non-malignant
gastrointestinal and liver disease, a higher level of
significance is obtained for the CEA. 11 assay than
for the T84.66 assay. In contrast, the T84.66 assay
shows a higher level of significance for carcinomas of
the hing vs. benign lung disease and for mammary
cancer vs. normal blood donors.
Discussion
Monoclonal anti-CEA antibodies bind to different
human carcinomas such s colorectal, mammary, and
lung carcinomas. According to their reactivity with
normal tissues, two major subgroups can be distin-
guished. One subgro p is characterized by antibody-
binding to normal granulocytes and/or bile canaliculi,
whereas monoclonal antibodies of the second
subgroup do not significantly cross-react with these
normal tissues (11, 13). In previous studies, we de-
scribed five monoclonal anti-CEA antibodies which
bind to different epitopes on CEA (10—12). Three of
these antibodies cross-re ct with gfanulocytes and/or
bile canaliculi. One of three cross-reactive antibodies
(T84.1) binds to products of each of the three CEA-
gene families described so far e.g. CEA, the non-
specific cross-reacting antigen, and the biliary glyco-^
proteinl (6, 8,14). Monoclonal antibody T84.l binds
CEA with high affiiiity (10, 22). The anti-CEA mon-
oclonal antibodies, which show no significant eross-
reactivity with granulocytes and bile canaliculi, sh w
a distinct antigen specificity. in addition to binding
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Fig. 5. Distribution of CEA-concentrations äs measured by 4 different immunoassays in malignant and non-malignant diseases.
(I) Abbott-assay; (II) Roche-Assay; (III) T84.1/T84.66 assay; (IV) T84.1/CEA. 11 assay.
The Wileoxon test was applied only to assays III and IV, because identical CEA-standard preparations were used in both
assay versions. This avpids the introduction of bias, which would arise from different speciflc activities of Standard
preparations.
(a) malignant disease: horizontal bars indicate the concentration ränge between the 25% and 75% percentiles. The numbers
refer to CEA-concentrations corresponding tö the 90% percentiles;
(b) non-malignant disease: horizontal bars indicate the concentrations between the 10% and 90% percentiles.
to CEA, monoclonal antibody CEA. 11 binds to a the Mr of CEAlow (125000) described by Hammer-
tumour-associated antigen with an-Mr of 128000 ström and co-workers (l 5). Structural studies suggest
(CRA-128). Monoclonal antibody T84.66 does not a close relationship to CEA (J. Shively, personal com-
cross-react with CRA-128 (14). Monoclonal antibod- muriicätion). Since CRA-128 does not bind mono-
ies with binding properties similar to monoclonal an- clonal antibodies against the non-specific cross-react-
tibody CEA. 11 have been described by Suzuki et al. ing antigen (unpublished observation), it is different
(16) and Schwarz et al. (17). from antigens related to the non-specific cross-react-
ing antigen. According to Barnett et al. (7), the MT of
The relationship ofCRA-128 to the different products CRA-128 would be eompatible with the product of
of the CEA gene family has not been established. The the unspliced transcript of the biliary glycoprotein I
relative molecular mass of the antigen is similar to gene published recently (6).
J. Clin. Chem. Clin. Biochem. / Vol. 27,1989 / No. 9
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Fig. 6. Discrimination between malignant and non-malignant conditions by two different CEA-immunoassays. Results of Kol-
mogoro v-Stnirno v-tests.
, 84.1/ 84.66 immunoassay; m, T84.1/CEA11 immunoassay.
According to recent Western blot studies, CRA-128
was found in 6/9 malignant tissues or effusions (un-
published observation). Furthermore, Suzuki et al.
(16) provided evidence that a related antigen is present
in serum samples from patients with malignant dis-
ease. These data indicate that the determination of
CRA-128 in serum may be of value in tumour diag-
nosis.
In order to answer the question of whether CRA-128
may appear in the blood of tumour patients, two
different additive solid phase immunöassays were es-
tablished. In both assays, the broadly cross-reactive
monoclonal antibody T84.1 was immobilized on a
solid support. Either monoclonal antibody T84.66 or
monoclonal antibody CEA. 11 was used äs the second
antibody. The specificities of these immunöassays
were analysed by the use of tumour extracts, in which
both CEA and CRA-128 had been shown to be pres-
ent by Western blots. After immunoadsorption of the
extracts to a T84.66 immunosorbent, no residual CEA
activity could be detected in the T84.66 immunoassay.
In contrast, residual antigen binding was demon-
strated by the CEA. 11 immunoassay. These data
show that the CEA. 11 immunoassay detects an an-
tigen which does not interfere in the T84.66 assay.
Like other investigators (23 — 26) we found that anti-
mouse IgG activity in sera of normal persons and
tumour patients can give rise to falsely elevated an-
tigen concentrations. In the T84.66 immunoassay, in
which antigen and antibodies are incubated for l h,
the unspecific interferences coüld be blocked by the
addition of 10 ml/l mouse serum. Because of the
longer incubation time of the CEA. 11 assay (17h),
this assay was mofe sensitive to interference by anti^
mouse IgG binding substances of low affmity, which
could not be eliminated by the addition of normal
mouse IgG even at high concentration. The unspecific
binding effects were eliminated by the use of F(ab)2-
fragments of monoclonal antibody T84.1 on the solid
phase.
Serum samples from patients with malignant and non-
malignant disease, äs well äs from apparently healthy
persons, were analysed by the above immunöassays
äs well äs by two commercial assays. The correlation
between the T84.66 assay and the commercial assays
was comparable with the correlation between the
commercial assays. A poorer correlation was observed
between the CEA. 11 assay and the remaining assays.
This finding may be related either to the distinct
antigen specificity of the CEA. 11 assay or to its higher
variance. The higher variance of the CEA. 11 assay is
probably due to the lower affinity of monoclonal
antibody CEA. 11 in comparison with monoclonal
antibody T84.66 (10).
The distributions of CEA concentrations in sera of
patients with colorectal cancer vs. non^malignaet gas-
trointestinal and liver disease were (Jiscriminated by
the CEA. 11 assay at a higher level of significance
than by the T84.66 assay (flg. 6). Höwever, a direct
comparison of the CEA concentrations determined
by the CEA. 11 and T84.66 immunöassays by Wil-
coxon's matched pairs signed rank test revealed no
J. Clin. Chem. Clin. Biochem. / Vol. 27,1989 / No. 9
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significant differences in patients with colorectal can-
cer or in patients with benign gastrointestinal and
liver disease. In the diagnosis of mammary and lung
cancer, the CEA. 11 immunoassay yielded signifi-
cantly lower CEA concentrations than the T84.66
assay. The diagnostic value of the CEA. 11 assay is
further limited by the finding that significantly higher
CEA values were observed in several non-malignant
conditions, notably in patients with non-malignant
kidney disease, including a significant number of pa-
tients with chronic renal failure. It has been reported
that the rate of false positives in chronic renal failure
differs considerably in different CEA immunoassays.
This finding may be explained by the epitope speci-
ficities of the antibodies.
The results reported here indicate that CRA-128, a
CEA related tumour-associated antigen with a rela-
tive molecular mass of 128000, is not significantly
elevated in the sera of patients with malignant disease.
Suzuki et al. (16) described an immunoassay with an
antigen specificity similar to the CEA. 11 assay. In
three serum specimens from tumour patients, signifi-
cantly elevated antigen concentrations remained after
adsorption to a CEA-specific immunosorbent. No
Information on the relative frequency of such serum
specimens among sera from tumour patients were
given. Though CRA-128 was detected in 6/9 extracts
from malignant tissues or effusions in malignant dis-
eases (unpublished observation), the release of CRA-
128 into the circulation seems not to be significant.
A possible explanation for this finding are the differ-
ences between the membrane anchors of CEA-related
antigens. CEA is anchored to the cell membrane via
phosphatidylinositol (27—29). It has been suggested
that the cleavage of CEA from the membrane by
endogenous phospholipase C may be critical for the
release into the blood stream (28). In contrast to the
CEA-gene, the gene coding for biliary glycoprotein I
predicts a transmembraneous and a cytoplasmic do-
main. If the MT 128000 antigen is anchored via the
latter mechanism, äs suggested by Barnett et al. (7),
it would not be easily released into the circulation.
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